Teva Pharmaceutical Industries (TEVA) said Sunday that it expects 2025 earnings to fall in the upper end of the $2.55 to $2.65 per diluted share range.
Analysts surveyed by FactSet expect $2.63.
The company expects revenue for the year at the lower end of the $16.8 billion to $17 billion range.
Analysts polled by FactSet expect $16.9 billion.
For 2026, the company anticipates revenue to remain flat or slightly lower compared with 2025, while for 2027, Teva said it expects low-single digit growth.
Analysts surveyed by FactSet expect revenue of $16.82 billion in 2026 and $17.25 billion in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments